XENLETA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug XENLETA contains one active pharmaceutical ingredient (API):

1	Lefamulin UNII HDN0B924X4 - LEFAMULIN ACETATE
	Lefamulin is a pleuromutilin antibacterial agent. It inhibits bacterial protein synthesis by interacting with the A- and P- sites of the peptidyl transferase centre (PTC) in the central part of domain V of the 23S rRNA of the 50S ribosomal subunit, preventing correct positioning of the tRNA.
	Read more about Lefamulin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XENLETA Concentrate and solvent for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
XENLETA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
XENLETA Solution for injection / Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01XX12		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XX Other antibacterials
Discover more medicines within J01XX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1824454, 1824465
IT	Agenzia del Farmaco	048963019, 048963021
LT	Valstybinė vaistų kontrolės tarnyba	1090897, 1090898
PL	Rejestru Produktów Leczniczych	100440180, 100440196
US	FDA, National Drug Code	72000-110, 72000-120